BioCentury | Sep 1, 2014
Company News

Imugene management update

Imugene Ltd. (ASX:IMU), Armadale, Australia Business: Drug delivery Hired: Charles Walker as CEO, formerly CEO of Alchemia Ltd. WIR Staff...
BioCentury | Jan 13, 2014
Company News

Biolife Science, Imugene deal

...for 300 million shares of Imugene stock, or about A$4.5 million ($4 million) based on Imugene's...
...before the deal closed (see BioCentury, Oct. 28, 2013). Biolife Science Ltd. , Brisbane, Australia Imugene Ltd....
BioCentury | Oct 28, 2013
Financial News

Imugene completes private placement

Imugene Ltd. (ASX:IMU), Armadale, Australia Business: Drug delivery Date completed: 10/23/13 Type: Private placement Raised: A$2.5 million ($2.4 million) Shares: 250 million Price: A$0.01 Shares after offering: 593.6 million Investors: Company director; private investors WIR...
BioCentury | Oct 28, 2013
Company News

Biolife Science, Imugene deal

...million) based on Imugene's close of A$0.012 on Oct. 18, before the deal was announced. Imugene...
...in breast cancer, with Phase II testing in gastric cancer slated to start in 2015. Imugene...
...acquired the company because of the HER-Vaxx asset and the "favorable" valuation of the company. Imugene...
BioCentury | Sep 20, 2004
Tools & Techniques

Sopping up bacteria

...to bacterial resistance. Last week, BioMimic was spun out of the University of Adelaide and Imugene Ltd....
BioCentury | Sep 20, 2004
Company News

Imugene, University of Adelaide deal

...will now pay BioMimic any resulting milestones and royalties from its ongoing RMT animal program. Imugene Ltd....
BioCentury | Oct 7, 2002
Company News

Imugene Ltd., Aventis, Merck deal

...initial payments, and if Merial exercises its option, IMU would receive sublicense fees and royalties. Imugene Ltd....
BioCentury | Jul 10, 2000
Clinical News

Lyme disease laboratory diagnostic regulatory update

The Mayo Foundation received U.S. Patent No. 6,045,804 covering a Lyme disease diagnostic that uses OspA deficient antigens from mutant Borrelia burgdorferi. The test, which is exclusively licensed to Imugen, is used to detect infection...
Items per page:
1 - 8 of 8
BioCentury | Sep 1, 2014
Company News

Imugene management update

Imugene Ltd. (ASX:IMU), Armadale, Australia Business: Drug delivery Hired: Charles Walker as CEO, formerly CEO of Alchemia Ltd. WIR Staff...
BioCentury | Jan 13, 2014
Company News

Biolife Science, Imugene deal

...for 300 million shares of Imugene stock, or about A$4.5 million ($4 million) based on Imugene's...
...before the deal closed (see BioCentury, Oct. 28, 2013). Biolife Science Ltd. , Brisbane, Australia Imugene Ltd....
BioCentury | Oct 28, 2013
Financial News

Imugene completes private placement

Imugene Ltd. (ASX:IMU), Armadale, Australia Business: Drug delivery Date completed: 10/23/13 Type: Private placement Raised: A$2.5 million ($2.4 million) Shares: 250 million Price: A$0.01 Shares after offering: 593.6 million Investors: Company director; private investors WIR...
BioCentury | Oct 28, 2013
Company News

Biolife Science, Imugene deal

...million) based on Imugene's close of A$0.012 on Oct. 18, before the deal was announced. Imugene...
...in breast cancer, with Phase II testing in gastric cancer slated to start in 2015. Imugene...
...acquired the company because of the HER-Vaxx asset and the "favorable" valuation of the company. Imugene...
BioCentury | Sep 20, 2004
Tools & Techniques

Sopping up bacteria

...to bacterial resistance. Last week, BioMimic was spun out of the University of Adelaide and Imugene Ltd....
BioCentury | Sep 20, 2004
Company News

Imugene, University of Adelaide deal

...will now pay BioMimic any resulting milestones and royalties from its ongoing RMT animal program. Imugene Ltd....
BioCentury | Oct 7, 2002
Company News

Imugene Ltd., Aventis, Merck deal

...initial payments, and if Merial exercises its option, IMU would receive sublicense fees and royalties. Imugene Ltd....
BioCentury | Jul 10, 2000
Clinical News

Lyme disease laboratory diagnostic regulatory update

The Mayo Foundation received U.S. Patent No. 6,045,804 covering a Lyme disease diagnostic that uses OspA deficient antigens from mutant Borrelia burgdorferi. The test, which is exclusively licensed to Imugen, is used to detect infection...
Items per page:
1 - 8 of 8